SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Latigo Biotherapeutics, Inc. (Name of Issuer)

Common Stock, par value $0.0001 per share (Title of Class of Securities)

(CUSIP Number)

09/30/2026 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Westlake BioPartners Fund I, L.P.
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 5,944,009.00 6 Shared Voting Power 5,944,009.00 7 Sole Dispositive Power 5,944,009.00 8 Shared Dispositive Power 5,944,009.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 5,944,009.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 9.0 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:  Row 5 - 5,944,009 shares, except that Westlake BioPartners GP I, LLC ("Westlake GP I"), the general partner of Westlake BioPartners Fund I, L.P. ("Westlake Fund I"), may be deemed to have sole voting power, and Dr. Beth C. Seidenberg ("Seidenberg"), the sole managing director of Westlake GP I, may be deemed to have sole power to vote these shares. Row 7 - 5,944,009 shares, except that Westlake GP I, the general partner of Westlake Fund I, may be deemed to have sole dispositive power, and Seidenberg, the sole managing director of Westlake GP I, may be deemed to have sole power to dispose of these shares.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Westlake BioPartners GP I, LLC
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 5,944,009.00 6 Shared Voting Power 5,944,009.00 7 Sole Dispositive Power 5,944,009.00 8 Shared Dispositive Power 5,944,009.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 5,944,009.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 9.0 %
12	Type of Reporting Person (See Instructions) OO

Comment for Type of Reporting Person:  Row 5 - 5,944,009 shares, all of which are owned directly by Westlake Fund I. Westlake GP I, the general partner of Westlake Fund I, may be deemed to have sole voting power, and Seidenberg, the sole managing director of Westlake GP I, may be deemed to have sole power to vote these shares. Row 7 - 5,944,009 shares, all of which are owned directly by Westlake Fund I. Westlake GP I, the general partner of Westlake Fund I, may be deemed to have sole dispositive power, and Seidenberg, the sole managing director of Westlake GP I, may be deemed to have sole power to dispose of these shares.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Westlake BioPartners Fund II, L.P.
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 5,160,847.00 6 Shared Voting Power 5,160,847.00 7 Sole Dispositive Power 5,160,847.00 8 Shared Dispositive Power 5,160,847.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 5,160,847.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 7.8 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:  Row 5 - 5,160,847 shares, except that Westlake BioPartners GP II, LLC ("Westlake GP II"), the general partner of Westlake BioPartners Fund II, L.P. ("Westlake Fund II"), may be deemed to have sole voting power, and Seidenberg, the sole managing director of Westlake GP II, may be deemed to have sole power to vote these shares. Row 7 - 5,160,847 shares, except that Westlake GP II, the general partner of Westlake Fund II, may be deemed to have sole dispositive power, and Seidenberg, the sole managing director of Westlake GP II, may be deemed to have sole power to dispose of these shares.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Westlake BioPartners GP II, LLC
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 5,160,847.00 6 Shared Voting Power 5,160,847.00 7 Sole Dispositive Power 5,160,847.00 8 Shared Dispositive Power 5,160,847.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 5,160,847.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 7.8 %
12	Type of Reporting Person (See Instructions) OO

Comment for Type of Reporting Person:  Row 5 - 5,160,847 shares, all of which are owned directly by Westlake Fund II. Westlake GP II, the general partner of Westlake Fund II, may be deemed to have sole voting power, and Seidenberg, the sole managing director of Westlake GP II, may be deemed to have shared power to vote these shares. Row 7 - 5,160,847 shares, all of which are owned directly by Westlake Fund II. Westlake GP II, the general partner of Westlake Fund II, may be deemed to have sole dispositive power, and Seidenberg, the sole managing director of Westlake GP II, may be deemed to have shared power to dispose of these shares.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Westlake BioPartners Opportunity Fund I, L.P.
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 2,094,813.00 6 Shared Voting Power 2,094,813.00 7 Sole Dispositive Power 2,094,813.00 8 Shared Dispositive Power 2,094,813.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,094,813.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 3.2 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:  Row 5 - 2,094,813 shares, except that Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"), the general partner of Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity Fund I"), may be deemed to have sole voting power, and Seidenberg, the sole managing director of Westlake Opportunity GP I, may be deemed to have sole power to vote these shares. Row 7 - 2,094,813 shares, except that Westlake Opportunity GP I, the general partner of Westlake Opportunity Fund I, may be deemed to have sole dispositive power, and Seidenberg, the sole managing director of Westlake Opportunity GP I, may be deemed to have sole power to dispose of these shares.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Westlake BioPartners Opportunity GP I, LLC
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 2,094,813.00 6 Shared Voting Power 2,094,813.00 7 Sole Dispositive Power 2,094,813.00 8 Shared Dispositive Power 2,094,813.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,094,813.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 3.2 %
12	Type of Reporting Person (See Instructions) OO

Comment for Type of Reporting Person:  Row 5 - 2,094,813 shares, all of which are owned directly by Westlake Opportunity Fund I. Westlake Opportunity GP I, the general partner of Westlake Opportunity Fund I, may be deemed to have sole voting power, and Seidenberg, the sole managing director of Westlake Opportunity GP I, may be deemed to have sole power to vote these shares. Row 7 - 2,094,813 shares, all of which are owned directly by Westlake Opportunity Fund I. Westlake Opportunity GP I, the general partner of Westlake Opportunity Fund I, may be deemed to have sole dispositive power, and Seidenberg, the sole managing director of Westlake Opportunity GP I, may be deemed to have sole power to dispose of these shares.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Dr. Beth C. Seidenberg
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 13,199,669.00 6 Shared Voting Power 13,199,669.00 7 Sole Dispositive Power 13,199,669.00 8 Shared Dispositive Power 13,199,669.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 13,199,669.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 19.9 %
12	Type of Reporting Person (See Instructions) IN

Comment for Type of Reporting Person:  Row 5 - 13,199,669 shares, of which 5,944,009 shares are held directly by Westlake Fund I, 5,160,847 shares are held directly by Westlake Fund II and 2,094,813 shares are held directly by Westlake Opportunity Fund I. Westlake GP I is the general partner of Westlake Fund I, Westlake GP II is the general partner of Westlake Fund II and Westlake Opportunity GP I is the general partner of Westlake Opportunity Fund I. Seidenberg, as the sole managing director of each of Westlake GP I, Westlake GP II and Westlake Opportunity GP I, may be deemed to have sole voting power over the shares held directly by each of Westlake Fund I, Westlake Fund II and Westlake Opportunity Fund I. Row 7 - 13,199,669 shares, of which 5,944,009 shares are held directly by Westlake Fund I, 5,160,847 shares are held directly by Westlake Fund II and 2,094,813 shares are held directly by Westlake Opportunity Fund I. Westlake GP I is the general partner of Westlake Fund I, Westlake GP II is the general partner of Westlake Fund II and Westlake Opportunity GP I is the general partner of Westlake Opportunity Fund I. Seidenberg, as the sole managing director of each of Westlake GP I, Westlake GP II and Westlake Opportunity GP I, may be deemed to have sole dispositive power over the shares held directly by each of Westlake Fund I, Westlake Fund II and Westlake Opportunity Fund I.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Latigo Biotherapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1300 Rancho Conejo Boulevard, Suite 305 Thousand Oaks, CA 91320
Item 2.
(a)	Name of person filing: This Statement is being filed by Westlake BioPartners Fund I, L.P. ("Westlake Fund I"), Westlake BioPartners GP I, LLC ("Westlake GP I"), Westlake BioPartners Fund II, L.P. ("Westlake Fund II"), Westlake BioPartners GP II, LLC ("Westlake GP II"), Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity Fund I"), Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I") and Dr. Beth C. Seidenberg ("Seidenberg") (collectively, the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each Reporting Person is c/o Westlake BioPartners, LLC, 3075 Townsgate Road, Suite 140, Westlake Village, California 91361.
(c)	Citizenship: Each of Westlake GP I, Westlake GP II and Westlake Opportunity GP I is a limited liability company organized under the laws of the State of Delaware. Each of Westlake Fund I, Westlake Fund II and Westlake Opportunity Fund I is a limited partnership organized under the laws of the State of Delaware. Seidenberg is a citizen of the United States of America.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),        please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of the cover page for each Reporting Person.*
(b)	Percent of class: See Row 11 of the cover page for each Reporting Person.*  %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of the cover page for each Reporting Person.*
	(ii) Shared power to vote or to direct the vote: See Row 6 of the cover page for each Reporting Person.*
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of the cover page for each Reporting Person.*
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of the cover page for each Reporting Person.*
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Under certain circumstances set forth in the limited partnership agreement of each of Westlake Fund I, Westlake Fund II and Westlake Opportunity Fund I and the limited liability company agreement of each of Westlake GP I, Westlake GP II and Westlake Opportunity GP I, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE
	After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Westlake BioPartners Fund I, L.P.

Signature: Westlake BioPartners GP I, LLC Name/Title: General Partner Date: 10/27/2026

Signature: /s/ Jennifer L. Kercher Name/Title: Jennifer L. Kercher/Attorney-in-Fact* Date: 10/27/2026

Westlake BioPartners GP I, LLC

Signature: /s/ Jennifer L. Kercher Name/Title: Jennifer L. Kercher/Attorney-in-Fact* Date: 10/27/2026

Westlake BioPartners Fund II, L.P.

Signature: Westlake BioPartners GP II, LLC Name/Title: General Partner Date: 10/27/2026

Signature: /s/ Jennifer L. Kercher Name/Title: Jennifer L. Kercher/Attorney-in-Fact* Date: 10/27/2026

Westlake BioPartners GP II, LLC

Signature: /s/ Jennifer L. Kercher Name/Title: Jennifer L. Kercher/Attorney-in-Fact* Date: 10/27/2026

Westlake BioPartners Opportunity Fund I, L.P.

Signature: Westlake BioPartners Opportunity GP I, LLC Name/Title: General Partner Date: 10/27/2026

Signature: /s/ Jennifer L. Kercher Name/Title: Jennifer L. Kercher/Attorney-in-Fact* Date: 10/27/2026

Westlake BioPartners Opportunity GP I, LLC

Signature: /s/ Jennifer L. Kercher Name/Title: Jennifer L. Kercher/Attorney-in-Fact* Date: 10/27/2026

Dr. Beth C. Seidenberg

Signature: /s/ Jennifer L. Kercher Name/Title: Jennifer L. Kercher/Attorney-in-Fact* Date: 10/27/2026

Exhibit Information

EXHIBIT INDEX Exhibit Description 1 Joint Filing Agreement 2 Power of Attorney - Westlake BioPartners Fund I, L.P. and Westlake BioPartners GP I, LLC 3 Power of Attorney - Westlake BioPartners Opportunity Fund I, L.P. and Westlake BioPartners Opportunity GP I, LLC 4 Power of Attorney - Westlake BioPartners Fund II, L.P. and Westlake BioPartners GP II, LLC

Exhibit 1

JOINT FILING AGREEMENT

The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the timely filing of such statement on Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness or accuracy of the information concerning the others of the undersigned, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate or incomplete. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

Dated: October 27, 2026

Exhibit 2

Power of Attorney

Each of the undersigned entities and individuals (collectively, the “Reporting Persons”) hereby authorizes and designates Westlake BioPartners GP I, LLC or such other person or entity as is designated in writing by Beth C. Seidenberg (the “Designated Filer”) as the beneficial owner to prepare and file on behalf of such Reporting Person individually, or jointly together with the other Reporting Persons, any and all reports, notices, communications and other documents (including, but not limited to, reports on Form D, Form ADV, Schedule 13D, Schedule 13F, Schedule 13G, Schedule 13H, Form 3, Form 4 and Form 5) that such Reporting Person may be required to file with the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (together with the implementing regulations thereto, the “Act”) and the Securities Exchange Act of 1934, as amended (together with the implementing regulations thereto, the “Exchange Act”) or any other domestic or international state, federal or national agency (collectively, the “Reports”) with respect to each Reporting Person’s ownership of, or transactions in, securities of any entity whose securities are beneficially owned (directly or indirectly) by such Reporting Person (collectively, the “Companies”).

Each Reporting Person hereby further (i) authorizes and designates Jennifer L. Kercher (the “Authorized Signatory”) to execute and file on behalf of such Reporting Person the Reports and to perform any and all other acts, which in the opinion of the Designated Filer or Authorized Signatory may be necessary or incidental to the performance of the foregoing powers herein granted and (ii) approves and ratifies all prior Reports executed and/or filed on behalf of each such Reporting Person by the Authorized Signatory.

The authority of the Designated Filer and the Authorized Signatory under this Power of Attorney with respect to each Reporting Person shall continue until such Reporting Person is no longer required to file any Reports with respect to the Reporting Person’s ownership of, or transactions in, the securities of the Companies, unless earlier revoked in writing. Each Reporting Person acknowledges that the Designated Filer and the Authorized Signatory are not assuming any of the Reporting Person’s responsibilities to comply with the Act or the Exchange Act.

Date: February 6, 2024

Exhibit 3

Power of Attorney

Each of the undersigned entities and individuals (collectively, the “Reporting Persons”) hereby authorizes and designates Westlake BioPartners Opportunity GP I, LLC or such other person or entity as is designated in writing by Beth C. Seidenberg (the “Designated Filer”) as the beneficial owner to prepare and file on behalf of such Reporting Person individually, or jointly together with the other Reporting Persons, any and all reports, notices, communications and other documents (including, but not limited to, reports on Form D, Form ADV, Schedule 13D, Schedule 13F, Schedule 13G, Schedule 13H, Form 3, Form 4 and Form 5) that such Reporting Person may be required to file with the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (together with the implementing regulations thereto, the “Act”) and the Securities Exchange Act of 1934, as amended (together with the implementing regulations thereto, the “Exchange Act”) or any other domestic or international state, federal or national agency (collectively, the “Reports”) with respect to each Reporting Person’s ownership of, or transactions in, securities of any entity whose securities are beneficially owned (directly or indirectly) by such Reporting Person (collectively, the “Companies”).

Each Reporting Person hereby further (i) authorizes and designates Jennifer L. Kercher (the “Authorized Signatory”) to execute and file on behalf of such Reporting Person the Reports and to perform any and all other acts, which in the opinion of the Designated Filer or Authorized Signatory may be necessary or incidental to the performance of the foregoing powers herein granted and (ii) approves and ratifies all prior Reports executed and/or filed on behalf of each such Reporting Person by the Authorized Signatory.

The authority of the Designated Filer and the Authorized Signatory under this Power of Attorney with respect to each Reporting Person shall continue until such Reporting Person is no longer required to file any Reports with respect to the Reporting Person’s ownership of, or transactions in, the securities of the Companies, unless earlier revoked in writing. Each Reporting Person acknowledges that the Designated Filer and the Authorized Signatory are not assuming any of the Reporting Person’s responsibilities to comply with the Act or the Exchange Act.

Date: February 6, 2024

Exhibit 4

Power of Attorney

Each of the undersigned entities and individuals (collectively, the “Reporting Persons”) hereby authorizes and designates Westlake BioPartners GP II, LLC or such other person or entity as is designated in writing by Beth C. Seidenberg (the “Designated Filer”) as the beneficial owner to prepare and file on behalf of such Reporting Person individually, or jointly together with the other Reporting Persons, any and all reports, notices, communications and other documents (including, but not limited to, reports on Form D, Form ADV, Schedule 13D, Schedule 13F, Schedule 13G, Schedule 13H, Form 3, Form 4 and Form 5) that such Reporting Person may be required to file with the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (together with the implementing regulations thereto, the “Act”) and the Securities Exchange Act of 1934, as amended (together with the implementing regulations thereto, the “Exchange Act”) or any other domestic or international state, federal or national agency (collectively, the “Reports”) with respect to each Reporting Person’s ownership of, or transactions in, securities of any entity whose securities are beneficially owned (directly or indirectly) by such Reporting Person (collectively, the “Companies”).

Each Reporting Person hereby further (i) authorizes and designates Jennifer L. Kercher (the “Authorized Signatory”) to execute and file on behalf of such Reporting Person the Reports and to perform any and all other acts, which in the opinion of the Designated Filer or Authorized Signatory may be necessary or incidental to the performance of the foregoing powers herein granted and (ii) approves and ratifies all prior Reports executed and/or filed on behalf of each such Reporting Person by the Authorized Signatory.

The authority of the Designated Filer and the Authorized Signatory under this Power of Attorney with respect to each Reporting Person shall continue until such Reporting Person is no longer required to file any Reports with respect to the Reporting Person’s ownership of, or transactions in, the securities of the Companies, unless earlier revoked in writing. Each Reporting Person acknowledges that the Designated Filer and the Authorized Signatory are not assuming any of the Reporting Person’s responsibilities to comply with the Act or the Exchange Act.

Date: May 4, 2023